Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
VT-464 inhibits CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|VT-464||Seviteronel|INO-464||Hormone - Anti-androgens 27||Seviteronel (VT-464) is a small molecule inhibitor of CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (PMID: 30012563, PMID: 25351916, PMID: 32327394).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate adenocarcinoma||not applicable||VT-464||Phase I||Actionable||In a Phase I study, VT-464 treatment led to safety and tolerability in patients with castration-resistant prostate adenocarcinoma and resulted in a best response of stable disease in 58% (10/17), a partial response in 6% (1/17), and no complete responses (PMID: 30012563; NCT02361086).||30012563|
|Unknown unknown||prostate cancer||no benefit||VT-464||Phase II||Actionable||In a Phase II trial, Seviteronel (VT-464) monotherapy demonstrated an undesirable toxicity profile and limited activity, with only 6% (1/17) of patients with metastatic castration-resistant prostate cancer achieved significant PSA response (PMID: 32327394).||32327394|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02580448||Phase Ib/II||VT-464||A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer||Completed|